AN2 Therapeutics (ANTX) Common Equity (2021 - 2026)
AN2 Therapeutics (ANTX) reported Common Equity of $75.92 million for Q2 2026, up 10.3% from $68.84 million a year earlier but down 7.1% from the prior quarter.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Common Equity (2021 - 2026) Analysis & Trends
At the end of FY2025, AN2 Therapeutics posted Common Equity of $53.06 million, down 35.2% from FY2024.
- By year, Common Equity came in at $81.85 million in FY2024 (-34.4%), $124.7 million in FY2023 (+30.8%), $95.37 million in FY2022 and -$47.41 million in FY2021.
- Five-year quarterly Common Equity spans a low of -$47.41 million in Q4 2021 and a high of $138.97 million in Q3 2023.
- Year over year, Common Equity gained in two of the last eight quarters, with an average decline of 22.4%.
- The high point for year-over-year Common Equity in five years was Q1 2024 (growth of 34.0%); the low point was Q3 2024 (a decline of 36.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $81.76 million (Q1 2026), $53.06 million (Q4 2025) and $60.38 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | AN2 Therapeutics | 181.91 Mn | 181.91 Mn | - | 75.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.92 Mn |
| Mar 31, 2026 | 81.76 Mn |
| Dec 31, 2025 | 53.06 Mn |
| Sep 30, 2025 | 60.38 Mn |
| Jun 30, 2025 | 68.84 Mn |
| Mar 31, 2025 | 73.33 Mn |
| Dec 31, 2024 | 81.85 Mn |
| Sep 30, 2024 | 87.67 Mn |
| Jun 30, 2024 | 98.35 Mn |
| Mar 31, 2024 | 110.60 Mn |
| Dec 31, 2023 | 124.70 Mn |
| Sep 30, 2023 | 138.97 Mn |
| Jun 30, 2023 | 87.76 Mn |
| Mar 31, 2023 | 82.52 Mn |
| Dec 31, 2022 | 95.37 Mn |
| Sep 30, 2022 | 105.57 Mn |
| Jun 30, 2022 | 115.86 Mn |
| Mar 31, 2022 | 115.41 Mn |
| Dec 31, 2021 | -47.41 Mn |
| Sep 30, 2021 | -38.35 Mn |
API Access
AN2 Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ANTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ANTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ANTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();